

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Clarity Pharmaceuticals Ltd</b>
<b>ABN</b>	<b>36 143 005 341</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Colin David Biggin
<b>Date of last notice</b>	4 July 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	n/a
<b>Date of change</b>	25 November 2025
<b>No. of securities held prior to change</b>	<ul style="list-style-type: none"><li>• 4,926,458 fully paid ordinary shares</li><li>• 837,855 options exercisable at \$0.508 each on or before 24 November 2027</li><li>• 557,393 options exercisable at \$0.793 each on or before 24 November 2028</li><li>• 371,595 options exercisable at \$0.721 each on or before 24 November 2028</li><li>• 99,679 options exercisable at \$5.505 each on or before 20 November 2029</li><li>• 186,239 options exercisable at \$5.005 each on or before 20 November 2029</li></ul>
<b>Class</b>	Options

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number acquired</b>	<ul style="list-style-type: none"> <li>199,909 options exercisable at \$2.30 each on or before 1 July 2030 (<b>Component A</b>)</li> <li>287,530 options exercisable at \$2.30 each on or before 1 July 2030 (<b>Component B</b>)</li> </ul>
<b>Number disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ul style="list-style-type: none"> <li><b>Component A:</b> Indicative value of \$267,878 using a Black-Scholes valuation using the 5-day VWAP of shares at 30 June 2025.</li> <li><b>Component B:</b> Indicative value of \$519,997 using a Monte Carlo simulation using the 5-day VWAP of shares at 30 June 2025.</li> </ul>
<b>No. of securities held after change</b>	<ul style="list-style-type: none"> <li>4,926,458 fully paid ordinary shares</li> <li>837,855 options exercisable at \$0.508 each on or before 24 November 2027</li> <li>557,393 options exercisable at \$0.793 each on or before 24 November 2028</li> <li>371,595 options exercisable at \$0.721 each on or before 24 November 2028</li> <li>99,679 options exercisable at \$5.505 each on or before 20 November 2029</li> <li>186,239 options exercisable at \$5.005 each on or before 20 November 2029</li> <li>487,439 options exercisable at \$2.30 each on or before 1 July 2030</li> </ul>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of options following approval at the Company's 2025 Annual General Meeting

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	n/a
<b>Nature of interest</b>	n/a
<b>Name of registered holder (if issued securities)</b>	n/a

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Date of change</b>	n/a
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	n/a
<b>Interest acquired</b>	n/a
<b>Interest disposed</b>	n/a
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	n/a
<b>Interest after change</b>	n/a

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	n/a
<b>If prior written clearance was provided, on what date was this provided?</b>	n/a

---

<sup>+</sup> See chapter 19 for defined terms.